[1] 中华医学会肝病学分会,中华医学会消化病学分会,中华医学会感染病学分会.原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识(2015).中华肝脏病杂志,2016,24(1):5-13. [2] Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D. The clinical usage and definition of autoantibodies in immune-mediated liver disease: A comprehensive overview. J Autoimmun, 2018,95:144-158. [3] Tanaka A, Leung PS, Gershwin ME. Environmental basis of primary biliary cholangitis. Exp Biol Med (Maywood), 2018,243(2):184-189. [4] Joshita S, Umemura T, Tanaka E,et al. Genetics and epigenetics in the pathogenesis of primary biliary cholangitis. Clin J Gastroenterol, 2018,11(1):11-18. [5] Galoosian A, Hanlon C, Zhang J, et al. Clinical updates in primary biliary cholangitis: trends, epidemiology, diagnostics, and new therapeutic approaches. J Clin Transl Hepatol, 2020, 8 (1):49-60. [6] Zeng N, Duan W, Chen S, et al. Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: a systematic review and meta-analysis. Hepatol Int, 2019, 13(6): 788- 799. [7] Jiang XH, Zhong RQ, Fan XY,et al. Characterization of M2 antibodies in asymptomatic Chinese population. World J Gastroenterol, 2003,9(9):2128-2131. [8] Liu H, Liu Y, Wang L,et al. Prevalence of primary biliary cirrhosis in adults referring hospital for annual health check-up in Southern China. BMC Gastroenterol, 2010, 10:100. [9] Lleo A, Jepsen P, Morenghi E, et al. Evolvingtrends in female to male incidence and male mortality of primary biliary cholangitis. Sci Rep, 2016,6:25906. [10] Onofrio FQ, Hirschfield GM, Gulamhusein AF. A practical review of primary biliary cholangitis for the gastroenterologist. Gastroenterol Hepatol (N Y), 2019 ,15(3):145-154. [11] Dahlan Y, Smith L, Simmonds D, et al. Pediatric-onset primary biliary cirrhosis. Gastroenterology, 2003,125(5):1476-1479. [12] 顾而立,姚光弼.中国人原发性胆汁性肝硬化的临床特点:52年文献的系统分析.中华肝脏病杂志,2009,17(11):861-866. [13] Yamagiwa S, Kamimura H, Takamura M,et al. Autoantibodies in primary biliary cirrhosis: recent progress in research on the pathogenetic and clinical significance. World J Gastroenterol, 2014,20(10):2606-2612. [14] Zhang Q, Liu Z, Wu S, et al. Meta-analysis of antinuclear antibodies in the diagnosis of antimitochondrial antibody-negative primary biliary cholangitis. Gastroenterol Res Pract, 2019,2019:8959103. [15] European association for the study of the liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol, 2009,51(2):237-267. [16] Leung PS, Rossaro L, Davis PA,et al. Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis. Hepatology, 2007, 46(5): 1436–1442. [17] Yang J, Yu YL, Jin Y,et al. Clinical characteristics of drug-induced liver injury and primary biliary cirrhosis. World J Gastroenterol, 2016, 22(33): 7579–7586. [18] Sebode M, Weiler-Normann C, Liwinski T,et al. Autoantibodies in autoimmune liver disease-clinical and diagnostic relevance. Front Immunol, 2018, 9: 609. [19] Dahlqvist G, Gaouar F, Carrat F, et al. Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis. Hepatology, 2017, 65(1):152-163. [20] Baldo DC, Dellavance A, Ferraz MLG, et al. Evolving liver inflammation in biochemically normal individuals with anti-mitochondria antibodies. Auto Immun Highl,2019,10(1):10. |